Hyperuricemia in patients with cancer

American Journal of Cancer

Volumn 1, Issue 6, 2002, Pages 409-422

  Ribeiro, Raul C ^a,b   Pui, Ching Hon ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CYCLOPHOSPHAMIDE; HYPOXANTHINE; NUCLEAR PROTEIN; RASBURICASE; RECOMBINANT ENZYME; URATE OXIDASE; URIC ACID; URICOZYME; XANTHINE; XANTHINE OXIDASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BRONCHOSPASM; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DIALYSIS; DRUG SENSITIVITY; EOSINOPHILIA; FEVER; HEMATOLOGIC MALIGNANCY; HEPATITIS; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERSENSITIVITY; HYPERURICEMIA; HYPOCALCEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY HYPERTROPHY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; TUMOR LYSIS SYNDROME;

EID: 0041317593     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200201060-00004     Document Type: Review

References (129)

1. Merrill D, Jackson H. The renal complications of leukemia. N Engl J Med 1943; 228 (9): 271-6
2. Rieselbach RE, Bentzel CJ, Cotlove E, et al. Uric acid excretion and renal function in the acute hyperuricemia of leukemia. Am J Med 1964; 37: 872-84
3. Conger JD. Acute uric acid nephropathy. Med Clin North Am 1990; 74 (4): 859-71
4. Perry MC, Hoagland HC, Wagoner RD. Uric acid nephropathy. JAMA 1976; 236 (8): 961-2
5. Zusman J, Brown DM, Nesbit ME. Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 1973; 289 (25): 1335-40
6. Cadman EC, Lunberg WB, Bertino JR. Hyperphosphatermia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. Am J Med 1977; 62 (2): 283-90
7. Pui CH. Optimal treatment of malignancies associated with hyperuricemia? Semin Hematol 2001; 38 Suppl. 10: 1-3
8. Cohen LF, Balow JE, Magrath IT, et al, Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68 (4): 486-91
9. Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol 1993; 13 (3): 273-80
10. Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38 (4 Suppl. 10): 4-8
11. Jones DP, Stapleton FB, Kalwinsky D, et al. Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Med Pediatr Oncol 1990; 18: (4): 283-6
12. Morley CJ, Houston IB, Morris-Jones P. Acute renal failure and gout as presenting features of acute lymphoblastic leukaemia. Arch Dis Child 1976; 51 (9): 723-5
13. Larsen G, Loghman-Adham M. Acute renal failure with hyperuricemia as initial presentation of leukemia in children. J Pediatr Hematol Oncol 1996; 18 (2): 191-4
14. Levin M, Cho S. Acute tumor lysis syndrome in high grade lymphoblastic lymphoma after a prolonged episode of fever. Med Pediatr Oncol 1996; 26 (6): 417-8
15. Jasek AM, Day HJ. Acute spontaneous tumor lysis syndrome. Am J Hematol 1994; 47 (2): 129-31
16. Loosveld OJ, Schouten HC, Gaillard CA, et al. Acute tumour lysis syndrome in a patient with acute lymphoblastic leukemia after a single dose of prednisone [published erratum appears in Br J Haematol 1991 Mar: 77 (3): 446]. Br J Haematol 1991; 77 (1): 122-3
17. Malik IA, Abubakar S, Alam F, et al. Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin's lymphoma. South Med J 1994; 87 (3): 409-11
18. Sparano J, Ramirez M, Wiernik PH. Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphoma. Cancer 1990; 65 (5): 1072-3
19. Simmons ED, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 1991; 67 (8): 2062-5
20. Lobe TE, Karkera MS, Custer MD, et al. Fatal refractory hyperkalemia due to tumor lysis during primary resection for hepatoblastoma. J Pediatr Surg 1990; 25 (2): 249-50
21. Cech P, Block JB, Cone LA, et al. Tumor lysis syndrome after tamoxifen flare. N Engl J Med 1986; 315 (4): 263-4
22. Rigas D, Duerst M, Jump ME, et al. The nucleic acids and other phosphorus compounds of human leukemic leukocytes: relation to cell maturity. J Lab Clin Med 1956; 48 (3): 356-78
23. Przepiorka D, Gonzales-Chambers R. Acute tumor lysis syndrome in a patient with chronic myelogenous leukemia in blast crisis: role of high-dose Ara-C. Bone Marrow Transplant 1990; 6 (4): 281-2
24. Lotfi M, Brandwein JM. Spontaneous acute tumor lysis syndrome in acute myeloid leukemia?: a single case report with discussion of the literature. Leuk Lymphoma 1998; 29 (5-6): 625-8
25. List AF, Kummet TD, Adams JD, et al. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 1990; 89 (3): 388-90
26. McCroskey RD, Mosher DF, Spencer CD, et al. Acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposide. Cancer 1990; 66 (2): 246-50
27. Schifter T, Cohen A, Lewinski UH. Severe tumor lysis syndrome following splenic irradiation. Am J Hematol 1999; 60 (1): 75-6
28. Nomdedeu J, Martino R, Sureda A, et al. Acute tumor lysis syndrome complicating conditioning therapy for bone marrow transplantation in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant 1994; 13 (5): 659-60
29. Castro MP, VanAuken J, Spencer-Cisek P, et al. Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer 1999; 85 (5): 1055-9
30. Drakos P, Bar-Ziv J, Catane R. Tumor lysis syndrome in nonhematologic malignancies: report of a case and review of the literature. Am J Clin Oncol 1994; 17 (6): 502-5
31. Rostom AY, El Hussainy G, Kandil A, et al. Tumor lysis syndrome following hemi-body irradiation for metastatic breast cancer. Ann Oncol 2000; 11 (10): 1349-51
32. Tomlinson GC, Solberg LA. Acute tumor lysis syndrome with metastatic medulloblastoma: a case report. Cancer 1984; 53 (8): 1783-5
33. Arseneau J, Canellos G, Banks P, et al. American Burkitt's lymphoma: a clinicopathologic study of 30 cases: I. clinical factors relating to prolonged survival. Am J Med 1975; 58 (3): 314-21
34. Brouland JP, Meeus F, Rossert J, et al. Primary bilateral B-cell renal lymphoma: a case report and review of the literature. Am J Kidney Dis 1994; 24 (4): 586-9
35. Obrador GT, Price B, O'Meara Y, et al. Acute renal failure due to lymphomatous infiltration of the kidneys. J Am Soc Nephrol 1997; 8 (8): 1348-54
36. Seidemann K, Meyer U, Jansen P, et al. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL: observations from the BFM-trials. Klin Padiatr 1998; 210 (4): 279-84
37. Stapleton F, Strother D, Roy S, et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic leukemia. Pediatrics 1988; 82 (6): 863-9
38. Arseneau JC, Bagley CM, Anderson T, et al. Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma. Lancet 1973; I (7793): 10-4
39. Brereton HD, Anderson T, Johnson RE, et al. Hyperphosphatemia and hypocalcemia in Burkitt lymophoma: complications of chemotherapy. Arch Intern Med 1975; 135 (2): 307-9
40. Ablin A, Stephens BG, Hirata T, et al. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism 1972; 21 (8): 771-8
41. Band P, Silverberg D, Henderson J, et al. Xanthine nephropathy in a patient wtih lymphosarcoma treated with allopurinol. N Engl J Med 1970; 283 (7): 354-7
42. Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones: a rare complications of allopurinol therapy. N Engl J Med 1969; 280 (8): 426-7
43. Holland P, Holland MH. Prevention and management of acute hyperuricemia in childhood leukemia. J Pediatr 1998; 72 (3): 358-66
44. Krakoff I. Xanthine oxidase inhibition in the management of hyperuricemia in leukemias and lymphomas. Arthritis Rheum 1965; 8 (5): 772-9
45. DeConti R, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med 1966; 274 (9): 481-6
46. Hitchings GH. Effects of allopurinol in relation to purine biosynthesis. Ann Rheum Dis 1966; 25 (6): 601-7
47. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol 1996; 14 (4): 1252-61
48. Pui CH. Rasburicase: a potent uricolytic agent? Expert Opin Pharmacother 2002; 3: 433-52
49. Laboureur P, Langlois C. Urate oxidase of Aspergillus flavus: I. Isolation, purification, properties. Bull Soc Chim Biol (Paris) 1968; 50 (4): 811-25
50. Laboureur P, Langlois C. Urate oxidase of Aspergillus flavus: II. metabolism, inhibition, specificity. Bull Soc Chim Biol (Paris) 1968; 50 (4): 827-41
51. Kissel P, Lamarche M, Royer R. Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature 1968; 217 (123): 72-4
52. Kissel P, Mauuary G, Royer R, et al. Treatment of malignant haemopathies and urate oxidase [letter]. Lancet 1975; 1 (7900): 229
53. Chanteclair G, Olive D. Acute hyperuricemic kidney failure: treatment by uricozyme [letter]. Nouv Presse Med 1975; 4 (31): 2274
54. Masera G, Jankovic M, Zurlo MG. et al. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982; 100 (1): 152-5
55. Masera G, Jankovic M. Tumor lysis syndrome, case report and review of the literature. Ann Oncol 1997; 8 (1): 97
56. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997; 11 (11): 1813-6
57. Mahmoud HH, Leverger G, Patte C, et al. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 1998; 77 Suppl. 4: 18-20
58. Pui CH. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001; 38 (4 Suppl. 10): 13-21
59. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19 (3): 697-704
60. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15 (10): 1505-9
61. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97 (10): 2998-3003
62. Moriwaki Y, Yamamoto T, Higashino K. Enzymes involved in purine metabolism: a review of histochemical localization and functional implications. Histol Histopathol 1999; 14 (4): 1321-40
63. Wu XW, Lee CC, Muzny DM, et al. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci U S A 1989; 86 (23): 9412-6
64. Wu XW, Muzny DM, Lee CC, et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34 (1): 78-84
65. Proctor P. Similar functions of uric acid and ascorbate in man? Nature 1970; 228 (274): 868
66. Friedman TB, Polanco GE, Appold JC, et al. On the loss of uricolytic activity during primate evolution: I. silencing of urate oxidase in a hominoid ancestor. Comp Biochem Physiol B 1985; 81 (3): 653-9
67. Ames BN, Cathcart R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981; 78 (11): 6858-62
68. Scott GS, Hooper DC. The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 2001; 56 (1): 95-100
69. Scott JT, Holloway VP, Glass HI, et al. Studies of uric acid pool size and turnover rate. Ann Rheum Dis 1969; 28 (4): 366-73
70. Glass HI, Scott JT, Gilles DC, et al. The interpretation of radioactive uric acid turnover data. Strahlentherapie [Sonderb] 1968; 67: 223-33
71. Lang F, Greger R, Oberleithner H, et al. Renal handling of urate in healthy man in hyperuricaemia and renal insufficiency: circadian fluctuation, effect of water diuresis and of uricosuric agents. Eur J Clin Invest 1980; 10 (4): 285-92
72. Lang F, Greger R, Sporer H, et al. Renal handling of urate and oxalate: possible implications for urolithiasis. Urol Res 1979; 7 (3): 143-8
73. Coe FL, Moran E, Kavalich AG. The contribution of dietary purine over-consumption to hyperpuricosuria in calcium oxalate stone formers. J Chronic Dis 1976; 29 (12): 793-800
74. Dodge HJ, Mikkelsen WM. Observations on the distribution of serum uric acid levels in participants of the Tecumseh, Michigan, Community Health Studies: a comparison of results of one method used at two different times and of two methods used simultaneously. J Chronic Dis 1970; 23 (3): 161-72
75. Munan L, Kelly A, PetitClerc C. Serum urate levels between ages 10 and 14: changes in sex trends. J Lab Clin Med 1977; 90 (6): 990-6
76. Campion EW, Glynn RJ, deLabry LO. Asymptomatic hyperuricemia: risks and consequences in the normative aging study. Am J Med 1987; 82 (3): 421-6
77. Price CP, James DR. Analytical reviews in clinical biochemistry: the measurement of urate. Ann Clin Biochem 1988; 25 (Pt 5): 484-98
78. Puig JG, Mateos FA, Ramos TH, et al. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2). Adv Exp Med Biol 1986; 195 Pt A: 317-23
79. Edwards NL, Fox IH. Disorders associated with purine and pyrimidine metabolism. In: Cohen MP, Foa PP, editors. Special topics in endocrinology and metabolism. New York: Alan R. Liss, 95-140
80. Stapleton FB. Renal uric acid clearance in human neonates. J Pediatr 1983; 103 (2): 290-4
81. Stapleton FB, Linshaw MA, Hassanein K, et al. Uric acid excretion in normal children. J Pediatr 1978; 92 (6): 911-4
82. Klinenberg JR. The effectiveness of allopurinol in the treatment of gout. Arthritis Rheum 1965; 8 (5): 891-5
83. Conger J, Falk S, Guggenheim S, et al. A micropuncture study of the early phase of acute urate nephropathy. J Clin Invest 1976; 58: 681-9
84. Conger J, Falk S. Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy. J Clin Invest 1977; 59 (5): 786-93
85. Wu X, Wakamiya M, Vaishnav S, et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 1994; 91 (2): 742-6
86. Fessel JW. Renal outcomes of gout and hyperuricemia. Am J Med 1979; 67: 74-82
87. Seegmiller JE, Rosenbloom FM, Kelley WN. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science 1967; 155 (770): 1682-4
88. Stout JT, Caskey CT. The Lesch-Nyhan syndrome: clinical, molecular and genetic aspects. Trends Genet 1988; 4 (6): 175-8
89. Lorentz WB, Burton BK, Trillo A, et al. Failure to thrive, hyperuricemia, and renal insufficiency in early infancy secondary to partial hypoxanthine-guanine phosphoribosyl transferase deficiency. J Pediatr 1984; 104 (1): 94-7
90. Ahmadian Y, Lewy PR. Possible urate nephropathy of the newborn infant as a cause of transient renal insufficiency. J Pediatr 1977; 91 (1): 96-100
91. Gottlieb RP, Roeloffs S, Galler-Rimm G, et al. Transient renal insufficiency in the neonate related to hyperuricemia and hyperuricosuria. Child Nephrol Urol 1991; 11 (2): 111-4
92. Adler R, Robinson R, Pazdral P, et al. Hyperuricemia in diarrheal dehydration. Am J Dis Child 1982; 136 (3): 211-3
93. Shenoi A, Phadke KD. Uric acid nephropathy as an unusual cause of actual renal failure in a neonate. Indian Pediatr 2000; 37 (3): 322-4
94. Knochel JP, Dotin LN, Hamburger RJ. Heat stress, exercise, and muscle injury: effects on urate metabolism and renal function. Ann Intern Med 1974; 81 (3): 321-8
95. Warren DJ, Leitch AG, Leggett RJ. Hyperuricaemic acute renal failure after epileptic seizures. Lancet 1975; II (7931): 385-7
96. Meisel AD, Diamond HS. Hyperuricosuria in the Fanconi syndrome. Am J Med Sci 1977; 273 (1): 109-15
97. Baldree LA, Stapleton FB. Uric acid metabolism in children. Pediatr Clin North Am 1990; 37 (2): 391-418
98. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995; 9 (2): 206-12
99. Holland J, Sharpe W, Mamrod L, et al. Urate excretion in patients with acute leukemia. J Natl Cancer Inst 1959; 23 (5): 1097-105
100. Mir MA. Renal excretion of uric acid and its relation to relapse and remission in acute myeloid leukaemia. Nephron 1977; 19 (2): 69-80
101. Hebert L, Lemann JJ, Petersen J, et al. Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 1966; 45 (12): 1886-94
102. Allon M, Llach F. Hyperphosphatemia, hypocalcemia, and renal failure in a patient with acute leukemia. Am J Kidney Dis 1988; 11 (5): 442-5
103. Monballyu J, Zachee P, Verberckmoes R, et al. Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin Nephrol 1984; 22 (1): 47-50
104. Kaplan BS, Hebert D, Morrell RE. Acute renal failure induced by hyperphosphatemia in acute lymphoblastic leukemia. Can Med Assoc J 1981; 124 (4): 429-31
105. Fox I, Palella T, Kelley W. Hyperuricemia: a marker for cell energy crisis. N Engl J Med 1987; 317 (2): 111-2
106. Sillos EM, Shenep JL, Burghen GA, et al. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer 2001; 92 (9): 2237-46
107. Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986; 109 (2): 292-8
108. Spielman WS, Thompson CI. A proposed role for adenosine in the regulation of renal hemodynamics and renin release. Am J Physiol 1982; 242 (5): F423-35
109. Hall J, Granger J, Hester R. Interactions between adenosine and angiotensin II in controlling glomerular filtration. Am J Physiol 1985; 248 (3 Pt 2): F340-6
110. Wolf G, Hegewisch-Becker S, Hossfeld DK, et al. Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 1999; 34 (5): E20
111. Leach M, Parsons RM, Reilly JT, et al. Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol 1998; 20 (3): 169-72
112. Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 1966; 15 (7): 863-80
113. Elion GB, Yu TF, Gutman AB, et al. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968; 45 (1): 69-77
114. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76 (1): 47-56
115. Fox IH, Kelley WN. Management of gout. JAMA 1979; 242 (4): 361-4
116. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40 (3): 245-9
117. Altman KI, Smull K, Guzman-Barron ES. A new method for the preparation of uncase and the effect of uricase on the blood uric acid levels of the chicken? Arch Biochem 1949; 21: 158-65
118. London M, Hudson PB. Uricolytic activity of purified uricase in two human beings. Science 1957; 125: 937-8
119. Ducros J, Saingra S, Rampal M, et al. Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient. Clin Nephrol 1991; 35 (2): 89-90
120. Patte C, Sakiroglu O, Sommelet D. European experience in the treatment of hyperuricemia. Semin Hematol 2001; 38 (4 Suppl. 10): 9-12
121. Atra A, Gerrard M, Hobson R, et al. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)-results of the UKCCSG 9003 protocol. Br J Cancer 1998; 77 (12): 2281-5
122. Cairo MS, Krailo MD, Morse M, et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced-non-lymphoblastic non-Hodgkin's lymphoma: a Children's Cancer Group Report. Leukemia 2002; 16: 594-600
123. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4 (12): 1732-9
124. Pattison ME, Lee SM, Ogden DA. Continuous arteriovenous hemodiafiltration: an aggressive approach to the management of acute renal failure. Am J Kidney Dis 1988; 11 (1): 43-7
125. Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol 1994; 8 (3): 351-3
126. Saccente SL, Kohaut EC, Berkow RL. Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Pediatr Nephrol 1995; 9 (5): 569-73
127. Agha-Razii M, Amyot SL, Pichette V, et al. Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol 2000; 54 (1): 59-63
128. Schelling JR, Ghandour FZ, Strickland TJ, et al. Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature. Ren Fail 1998; 20 (4): 635-44
129. Pichette V, Leblanc M, Bonnardeaux A, et al. High dialysate flow rate continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis 1994; 23 (4): 591-6